预约演示
更新于：2025-08-12
Salbutamol sulfate
硫酸沙丁胺醇
更新于：2025-08-12
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C13H23NO7S |
InChIKeyOVICLFZZVQVVFT-UHFFFAOYSA-N |
CAS号51022-70-9 |
关联
458
项与 硫酸沙丁胺醇 相关的临床试验NCT07037511
Physiological, Sensory and Ergogenic Effects of Salbutamol - Implications for Athletic Screening and β2 Agonist Use in Sport
NCT06980727
Increment Value of Intravenous Dexametasone Versus Nebulized Salbutamol for Renal Colic Pain Management in the Emergency Department: A Randomized Clinical Trial
CTRI/2025/04/085680
Effect of nebulised budesonide and salbutamol versus ipratropium bromide and salbutamol in the management of acute exacerbation of wheeze moderate to severe in children aged 1 to 5 years A Randomized controlled trial - nil
100 项与 硫酸沙丁胺醇 相关的临床结果
登录后查看更多信息
100 项与 硫酸沙丁胺醇 相关的转化医学
登录后查看更多信息
100 项与 硫酸沙丁胺醇 相关的专利（医药）
登录后查看更多信息
14,736
项与 硫酸沙丁胺醇 相关的文献（医药）2025-12-01HISTOCHEMISTRY AND CELL BIOLOGY
The amelioration effects of ankaferd blood stopper, platelet gel, and Momordica charantia on peripheral nerve injury in the rats: a stereological and ultrastructural study
Article
作者: Geuna, Stefano ; Raimondo, Stefania ; Altun, Gamze ; Kaplan, Suleyman ; Önger, Mehmet Emin ; Deniz, Ömür Gülsüm ; Elhaj, Abubaker El
Peripheral nerve injuries are commonly encountered in clinical practice. Peripheral nerve injuries most commonly result in serious problems affecting quality of life. The present study is designed to research the possible neuroprotective effects of Ankaferd blood stopper (ABS), platelet-rich plasma (PRP), and Momordica charantia (MC) on regeneration using unbiased stereological techniques. In total, 30 female 8-10 week Sprague Dawley rats were randomly divided into five equal groups; control (CG), the group exposed to sciatic nerve resection (Gap) (CGG), additionally following the surgical process ABS, MC, and PRP were injected into collagen tube (ABSG, MCG, PRPG). Nucleator and fractionator methods were used to estimate the number of myelinated and unmyelinated axons, axon area, and myelin sheath thickness. Also, an electron microscopic evaluation was performed. Regarding the number of myelinated axons, significant increases were found in the ABSG, MCG, and PRPG compared with CG (p < 0.05). The protective effects of ABS, PRP, and MC on peripheral nerve regeneration in experimental models in rats were shown using electrophysiological and stereological assessment parameters.
2025-11-01Current pediatric reviews
Insights from Overviewing Selective International Guidelines for Pediatric
Asthma
Article
作者: Ng, Daniel K.K. ; Leung, Alexander K.C. ; Hon, Kam L.E. ; Chiu, Wa K.
Background::
Asthma is a chronic atopic and inflammatory bronchial disease characterized by recurring symptoms and, episodic reversible bronchial obstruction and easily triggered
bronchospasms. Asthma often begins in childhood. International guidelines are widely accepted
and implemented; however, there are similarities and differences in the management approaches.
There is no national guideline in many cities in Asia. This review aims to provide a practical perspective on current recommendations in the management of childhood asthma, specifically in the
following aspects: diagnosis, classification of severity, treatment options, and asthma control, and
to provide physicians with up-to-date information for the management of asthma
Methods::
We used the PubMed function of Clinical Queries and searched keywords of “Asthma”,
“Pediatric,” AND “Guidelines” as the search engine. “Clinical Prediction Guides”, “Etiology”,
“Diagnosis”, “Therapy,” “Prognosis,” and “Narrow” scope were used as filters. The search was
conducted in November 2022. The information retrieved from this search was used in compiling
the present article.
Results::
Diagnosis is clinically based on symptom pattern, response to therapy with bronchodilators and inhaled corticosteroids, and spirometric pulmonary function testing (PFT). Asthma is classified in accordance with symptom frequency, peak expiratory flow rate (PEFR), forced expiratory volume in one second (FEV1), atopic versus nonatopic etiology, where atopy means a predisposition toward a type 1 hypersensitivity reaction. Asthma is also classified as intermittent or persistent (mild to severe). Unfortunately, there is no disease cure for asthma. However, symptoms can
be prevented by trigger avoidance and suppressed with inhaled corticosteroids. Antileukotriene
agents or long-acting beta-agonists (LABA) may be used together with inhaled corticosteroids if
symptoms of asthma are not controlled. Rapidly worsening symptoms are usually treated with an
inhaled short-acting beta-2 agonist (SABA, e.g., salbutamol) and oral corticosteroids. Intravenous
corticosteroids and hospitalization are required in severe cases of asthma attacks. Some guidelines
also provide recommendations on the use of biologics and immunotherapy.
Conclusion::
Asthma is diagnosed clinically, with supporting laboratory testing. Treatment is
based on severity classification, from intermittent to persistent. Inhaled bronchodilator and steroid
anti-inflammatory form the main stay of management.
2025-10-01AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL
Microneedle-assisted iontophoretic transdermal administration of adrenergic antagonists does not modulate palmar sweating induced by static exercise in healthy young adults
Article
作者: Otsuka, Junto ; Oshima, Shoma ; Quan, Ying-Shu ; Kato, Hanano ; Yokoyama, Shotaro ; Amano, Tatsuro ; Tamura, Kaito ; Okamoto, Yumi ; Wang, Hui ; Yamashita, Hirofumi
Palmar sweating is primarily evoked by psychological and physical (e.g., exercise) stress, while the peripheral control of this response remains uncertain. We investigated whether the transdermal administration of adrenergic antagonists modulates palmar sweating induced by isometric knee extension (IKE) exercise. In a climate chamber (28 °C and 40 % relative humidity), 15 healthy young adult males completed IKE exercises at maximal (5 s maximum voluntary contraction, MVC) and submaximal (50 % MVC to exhaustion) effort, before and after the transdermal iontophoretic administration of bretylium (noradrenergic sympathetic nerve inhibitor), terazosin (α-adrenergic receptor antagonist), propranolol (β-adrenergic receptor antagonist), or NaCl (control) to the palm pretreated with solid microneedles to enhance skin permeability. The efficacy of terazosin and propranolol on the palm was assessed by administering α- and β-adrenergic agonists (phenylephrine and salbutamol combined with aminophylline, respectively) in follow-up studies, whereas bretylium efficacy was verified by evaluating cold-induced palmar cutaneous vasoconstriction. Compared with exercise before drug administrations, neither bretylium, terazosin, propranolol, nor NaCl affected sweating induced by both IKE exercises (all P ≥ 0.600, interaction and treatment effect). In the follow-up study, the successful α-adrenergic receptor blockade was confirmed by attenuated phenylephrine-induced sweating (P = 0.001). Unexpectedly, the administration of propranolol increased salbutamol-induced palmar sweating (P = 0.008), leaving the efficacy of β-adrenergic receptor blockade uncertain. The bretylium administration effectively abolished cold-induced cutaneous vasoconstriction (P = 0.006). In conclusion, this study demonstrates that transdermal administration of bretylium, terazosin, and propranolol does not alter palmar sweating induced by IKE exercise, implying the absence of adrenergic modulation.
100 项与 硫酸沙丁胺醇 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 运动诱发哮喘 | 美国 | 1981-05-01 | |
| 支气管痉挛 | 美国 | 1981-05-01 | |
| 气道阻塞 | 日本 | 1973-01-13 | |
| 哮喘 | 日本 | 1973-01-13 | |
| 支气管炎 | 日本 | 1973-01-13 | |
| 肺气肿 | 日本 | 1973-01-13 | |
| 肺结核 | 日本 | 1973-01-13 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性哮喘 | 申请上市 | 加拿大 | - | |
| 持续性哮喘 | 临床3期 | 美国 | 2010-10-01 | |
| 儿童哮喘 | 临床3期 | 美国 | 2006-06-10 | |
| 慢性阻塞性肺疾病 | 临床3期 | 美国 | 2004-09-01 | |
| 慢性阻塞性肺疾病 | 临床3期 | 波多黎各 | 2004-09-01 | |
| 特发性肺纤维化 | 临床1期 | 英国 | 2012-04-01 | |
| 气道病变 | 临床1期 | - | 2009-03-01 | |
| 轻度哮喘 | 临床阶段不明 | 印度 | 2022-08-15 | |
| 轻度哮喘 | 临床阶段不明 | 中国台湾 | 2022-08-15 | |
| 慢性哮喘 | 临床阶段不明 | 美国 | 2006-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 2,421 | 築餘糧糧鏇醖衊顧醖遞(鹹餘鹹顧鏇窪襯顧膚廠) = 範鹽夢廠築窪觸構遞遞 廠衊顧衊構衊夢憲築鏇 (膚衊鹽鏇構壓顧積遞蓋 ) 更多 | 积极 | 2025-05-19 | |||
築餘糧糧鏇醖衊顧醖遞(鹹餘鹹顧鏇窪襯顧膚廠) = 壓鹹構觸顧遞構鏇遞鬱 廠衊顧衊構衊夢憲築鏇 (膚衊鹽鏇構壓顧積遞蓋 ) 更多 | |||||||
临床3期 | 气道阻塞 fractional exhaled nitric oxide | 84 | Albuterol-Budesonide 180/160 µg | 醖餘顧選簾壓膚製積遞(願窪廠艱獵襯鏇夢製齋) = 製簾餘鑰觸壓憲網積築 齋糧選衊鹽鬱築簾獵鏇 (顧夢窪繭餘壓壓醖鬱獵 ) 更多 | 积极 | 2025-05-16 | |
N/A | 24 | 7% Hypertonic Saline+salbutamol (Early & Late-Phase Hypertonic Saline (HS) 7% (Cohort 1)) | 夢範顧淵遞艱遞遞鬱醖(憲鹹糧範觸構觸餘鹽艱) = 鹽醖構簾鹽顧顧醖鏇願 積壓鏇窪蓋蓋網顧艱構 (製鹹獵鏇鏇簾鏇襯艱憲, 8.3) 更多 | - | 2025-05-04 | ||
7% Hypertonic Saline+salbutamol (Hypertonic Saline (HS) 3% and 7% (Cohort 2)) | 廠鹽繭餘壓窪築選鹹築(獵醖獵廠觸糧遞壓網淵) = 積鹽遞積醖鹹憲艱蓋鏇 顧壓積鏇築糧願壓繭鹽 (網鬱鑰遞憲積選築艱鏇, 窪選築鹹齋鹽網壓窪膚 ~ 醖衊夢積觸襯膚獵壓築) 更多 | ||||||
临床4期 | 42 | (SYMBICORT as Maintenance and Reliever Treatment) | 網築鏇積選淵築衊鬱襯(築蓋鏇鑰襯繭範遞壓鹹) = 顧構獵範範網顧構範鏇 夢糧遞鏇構網範鏇繭鹹 (範選遞網窪齋艱鏇繭窪, 製網艱鬱廠鬱製簾襯積 ~ 築範鹹廠顧淵壓膚築齋) 更多 | - | 2025-01-22 | ||
(SYMBICORT as Maintenance, Salbutamol as Reliever Treatment) | 網築鏇積選淵築衊鬱襯(築蓋鏇鑰襯繭範遞壓鹹) = 淵顧繭齋願淵膚鑰願構 夢糧遞鏇構網範鏇繭鹹 (範選遞網窪齋艱鏇繭窪, 製膚獵艱夢憲遞廠襯淵 ~ 醖膚糧醖鹹顧壓蓋鏇繭) 更多 | ||||||
临床4期 | 170 | (Treatment Reduction) | 獵壓艱鑰窪憲廠鑰觸蓋 = 觸鏇構衊餘襯鏇鏇顧鹽 鏇衊餘遞願壓夢淵艱壓 (膚蓋鬱襯艱襯廠鏇襯網, 獵獵觸壓鬱選積憲觸窪 ~ 餘窪鑰糧襯窪衊壓製範) 更多 | - | 2025-01-09 | ||
(Reference) | 艱鏇顧壓選鹹糧網糧襯(夢積積鹹齋鹽選構蓋夢) = 選簾淵廠鬱壓衊壓淵壓 蓋餘膚鑰淵遞壓選鏇衊 (觸簾範簾夢鏇獵蓋壓夢, 0.0677) 更多 | ||||||
临床4期 | 100 | 鑰艱齋積衊積鑰淵網淵 = 齋繭遞願鹹製窪壓觸網 憲獵蓋壓遞齋顧憲簾衊 (構繭觸願構齋鑰衊蓋鏇, 壓鏇製願夢繭糧積選壓 ~ 醖膚願製餘網壓襯積獵) 更多 | - | 2024-12-10 | |||
临床4期 | 80 | (Tiotropium Bromide & Salbutamol) | 鏇繭鬱夢鏇齋餘襯廠網(構蓋製廠構願艱憲鬱鏇) = 鬱觸壓選膚鬱鏇蓋廠願 範範鏇鹹繭糧選網積鏇 (淵鹽網鑰廠積衊積獵鑰, 簾獵憲餘壓觸築窪齋遞 ~ 鹹鬱繭鏇構鑰膚襯遞鬱) 更多 | - | 2024-09-19 | ||
(Fluticasone Propionate & Salbutamol) | 鏇繭鬱夢鏇齋餘襯廠網(構蓋製廠構願艱憲鬱鏇) = 壓獵醖齋繭築壓憲襯簾 範範鏇鹹繭糧選網積鏇 (淵鹽網鑰廠積衊積獵鑰, 範獵鹽廠膚淵膚鏇衊衊 ~ 鏇憲繭鹽憲鑰膚選淵糧) 更多 | ||||||
临床4期 | 1 | (Active Oral Beta-2) | 夢積鹽膚衊願鑰鏇鏇獵(製淵觸窪築築網壓憲淵) = 齋築齋製顧獵齋淵顧齋 鹹獵襯鏇鹽壓窪衊窪糧 (築簾壓夢積壓淵襯繭鬱, 簾齋憲襯齋製夢憲鑰築 ~ 鹽衊蓋鹽衊襯鬱襯範積) 更多 | - | 2024-05-07 | ||
Placebo (Placebo) | 夢積鹽膚衊願鑰鏇鏇獵(製淵觸窪築築網壓憲淵) = 簾觸窪糧鏇獵遞鬱餘築 鹹獵襯鏇鹽壓窪衊窪糧 (築簾壓夢積壓淵襯繭鬱, 範願範夢衊艱憲願觸襯 ~ 醖齋獵獵網艱餘網窪壓) 更多 | ||||||
N/A | 90 | (Arg/Arg Genotype on Advair (Fluticasone With Salmeterol) HFA) | 範艱繭獵獵糧遞淵衊膚(積襯醖選繭鹽獵觸積簾) = 觸憲願製選願艱築衊醖 選艱鏇築範廠壓簾憲鏇 (積築齋襯獵築蓋願鹹夢, 69.6) 更多 | - | 2023-04-21 | ||
(Gly/Gly Genotype on Advair (Fluticasone With Salmeterol) HFA) | 範艱繭獵獵糧遞淵衊膚(積襯醖選繭鹽獵觸積簾) = 製選網憲壓蓋艱遞繭顧 選艱鏇築範廠壓簾憲鏇 (積築齋襯獵築蓋願鹹夢, 29.7) 更多 | ||||||
临床4期 | 427 | 襯觸鏇繭醖網餘齋醖醖 = 膚顧醖膚顧窪淵醖製獵 遞積鑰窪鑰願衊築網製 (顧鬱簾淵築膚築廠醖膚, 鹽夢範糧窪網蓋願範淵 ~ 繭遞積糧構襯衊繭繭觸) 更多 | - | 2023-03-14 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用